Blog

ESMO updates from Presidential Symposium- European Society for Medical Oncology (ESMO)

Photo taken from dailyreporter.esmo.org

Oct 24, 2023, 14:57

ESMO updates from Presidential Symposium- European Society for Medical Oncology (ESMO)

“Positive outcomes in advanced or metastatic urothelial carcinoma reported from EV-302/KEYNOTE-A39 and CheckMate 901 indicate immunotherapy and Antibody Drug Conjugates (ADCs) as an alternative to first-line chemotherapy for the first time.

Results presented at today’s Presidential Symposium at ESMO23 show that enfortumab, vedotin plus pembrolizumab and adding nivolumab to chemotherapy prolonged median Progression-free survival (PFS) and median overall survival (OS) compared with chemotherapy.

Andrea Apolo, Bethesda, USA, comments on these findings on the ESMO Daily Reporter.
Read the full article here.”

Source:

Andrea Apolo Antibody Drug Conjugates (ADCs) Bethesda cancer ESMO Daily Reporter ESMO23 European Society for Medical Oncology (ESMO) immunotherapy OncoDaily Oncology

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage